Le Lézard
Classified in: Covid-19 virus
Subjects: MAV, CFG

Media Advisory - Deputy Prime Minister's itinerary for Thursday, September 24, 2020


OTTAWA, ON, Sept. 24, 2020 /CNW/ -

Note: All times local

Ottawa, Ontario



11:30 a.m.

The Deputy Prime Minister and Minister of Employment, Workforce Development and Disability Inclusion Carla Qualtrough will hold a media availability about the government's response to COVID-19.




Room 225


West Block


Parliament Hill




Notes for media:




  • Open coverage
  • Media are asked to arrive no later than 11:15 a.m.
  • Journalists can dial in to listen and ask questions to the Deputy Prime Minister and Minister Qualtrough.
  • Participant dial-in numbers:
    Local: 613-960-7519
    Toll-free: 1-877-413-4814
    Passcode: 6376356#

This document is also available at https://deputypm.canada.ca

SOURCE Deputy Prime Minister's Office


These press releases may also interest you

at 07:00
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") for violations of 10(b) and 20(a) of the Securities...

at 07:00
YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

at 06:40
The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation . Shareholders who...

at 06:00
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...



News published on and distributed by: